Analysts’ Opinions Are Mixed on These Healthcare Stocks: Augmedix (AUGX), Biodesix (BDSX) and Bioventus (BVS)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Augmedix (AUGX – Research Report), Biodesix (BDSX – Research Report) and Bioventus (BVS – Research Report).

Augmedix (AUGX)

In a report released yesterday, Allen Klee from Maxim Group initiated coverage with a Buy rating on Augmedix and a price target of $8.00. The company’s shares closed last Tuesday at $5.15, close to its 52-week high of $5.97.

According to TipRanks.com, Klee has 0 stars on 0-5 stars ranking scale with an average return of -22.5% and a 22.6% success rate. Klee covers the Technology sector, focusing on stocks such as T Stamp, Inc. Class A, ARB IOT Group Limited, and Research Solutions.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Augmedix with a $7.38 average price target, implying a 37.4% upside from current levels. In a report issued on October 27, Lake Street also maintained a Buy rating on the stock with a $8.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Biodesix (BDSX)

Canaccord Genuity analyst Kyle Mikson CFA maintained a Buy rating on Biodesix yesterday and set a price target of $3.50. The company’s shares closed last Tuesday at $1.48.

According to TipRanks.com, CFA is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -26.1% and a 14.5% success rate. CFA covers the Healthcare sector, focusing on stocks such as Castle Biosciences, Guardant Health, and Exact Sciences.

Currently, the analyst consensus on Biodesix is a Moderate Buy with an average price target of $3.50.

Bioventus (BVS)

In a report released yesterday, William Plovanic from Canaccord Genuity maintained a Hold rating on Bioventus, with a price target of $3.66. The company’s shares closed last Tuesday at $3.61.

According to TipRanks.com, Plovanic is a 2-star analyst with an average return of 0.2% and a 44.2% success rate. Plovanic covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Merit Medical Systems, and Irhythm Technologies.

Bioventus has an analyst consensus of Moderate Buy, with a price target consensus of $3.66.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on AUGX:

• Augmedix reports Q3 EPS (10c), consensus (12c)
• Augmedix Delivers 50% Revenue Growth and Expanded Gross Margins for Third Quarter of 2023
• Is AUGX a Buy, Before Earnings?
• Augmedix to Announce Third Quarter 2023 Financial Results and Host Investor Conference Call on November 6, 2023
• Augmedix price target raised to $8 from $6 at Lake Street